Enhancement of rat hepatic macrophages by treatment with interleukin-2 and streptococcal preparation OK432, with reference to antitumor activity, soluble factor production and Ia expression.
The effect of biological response modifiers, such as interleukin-2 (IL-2) and streptococcal preparation OK432, on the functions of hepatic macrophages was investigated. The macrophages, even with no exogenous stimulation, produced superoxide anion (O2-) and tumor necrosis factor (TNF), displayed cytotoxicity against K562 cells and cytostasis against P815 cells and expressed immune-region-associated antigen (Ia). IL-2 administered in vitro or in vivo enhanced O2- production by hepatic macrophages and the intravenous injection of OK432 also enhanced O2 production. Furthermore, IL-2 added to the culture medium of hepatic macrophages isolated from OK432-injected rats augmented O2- production even more. The TNF production and Ia expression of the macrophages were also increased by the intravenous injection of OK432. As with O2- production, the cytotoxicity of the cells was enhanced by OK432 injection or by IL-2 added to the culture medium and the combination of OK432 and IL-2 augmented their cytotoxicity even more. Thus, the present study suggested that IL-2 and OK432 induce the augmentation of the antitumor activity of hepatic macrophages, partly as a result of the increase in production of O2- and TNF and Ia expression.
Sasaoki
T
T
First Department of Surgery, Kyoto University School of Medicine, Japan.
Arii
S
S
Monden
K
K
Itai
S
S
Adachi
Y
Y
Funaki
N
N
Higashituji
H
H
Tobe
T
T
D000818:Animals; D001345:Autoradiography; D002250:Carbon Radioisotopes; D002448:Cell Adhesion / Q000502:physiology; D003602:Cytotoxicity, Immunologic; D000949:Histocompatibility Antigens Class II / Q000502:physiology*; D006801:Humans; D007155:Immunologic Factors / Q000494:pharmacology; D007376:Interleukin-2 / Q000494:pharmacology*; D008099:Liver / Q000166:cytology* / Q000187:drug effects; D008264:Macrophages / Q000187:drug effects* / Q000276:immunology / Q000502:physiology; D008297:Male; D009374:Neoplasms, Experimental / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D010844:Picibanil / Q000493:pharmacokinetics / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D013481:Superoxides / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000187:drug effects; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
D002250:Carbon Radioisotopes; D000949:Histocompatibility Antigens Class II; D007155:Immunologic Factors; D007376:Interleukin-2; D014409:Tumor Necrosis Factor-alpha; D013481:Superoxides; D010844:Picibanil